Regenerative and longevity cases turn on a question most experts are poorly placed to answer: what did the evidence actually support at the time the therapy was sold? These clinics operate in the space between promising early research and established practice — and their marketing borrows the language of the former while charging for the certainty of the latter.
As a clinician-investigator in longevity and regenerative endocrinology — and Director of the AI Academy at the Geneva College of Longevity Science — I can locate a given protocol precisely on that spectrum: what the trials show, what the regulators have said, what a careful physician would have disclosed, and where a defendant's claims crossed from optimism into misrepresentation.